Tolvaptan or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same for use in a method of reducing cardiotoxicity and/or improving survival from doxorubicin chemotherapy

摘要

The present invention relates to methods of reducing cardiotoxicity and/or improving survival from treatment with anthracycline agents comprising administering a therapeutically effective amount of a composition comprising a vasopressin antagonist compound or a pharmaceutically acceptable salt thereof as an active ingredient, administered simultaneously or prior to the anthracycline administration.